Geftinat 250mg Tablet

Non-small cell lung cancer

Geftinat 250mg Tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.

• Diarrhea
• Fever 
• Allergic skin reaction
• Nausea and Vomiting
• Increase in liver enzyme levels
• Eye irritation
• Difficulty in breathing
• Abdominal pain 
• Sore throat 
• Redness around fingernails 
• Unusual bleeding (in cough and urine), eye irritation or pain, swelling of the ankles or feet 
• Interstitial lung disease
  

• The doctor will recommend the dose strength and frequency of your dose as per your health condition and the body’s tolerance.
• Take the tablet as a whole with water.
• Do not crush or cut it.
• Get emergency medical treatment and contact your physician in case of overdose.

It consists of Gefitinib, which is a medication used for anticancer purposes and acts as a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR). Gefitinib exerts its action by stopping the phosphorylation of the tyrosine kinase that is linked to EGFR. Through interfering with such abnormal behavior of the protein, Geftinat prevents the development and spreading of the cancerous cells. The medicine exists in the form of an oral tablet with a strength of 250 mg.

If you miss a dose of medicine, do not double the dose. Consult your doctor for clarity. 

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Ghosh, R., Rajendranath, R., & Ganesan, P. (2019). A comparative observational study on erlotinib and gefitinib in NSCLC: Tolerability and clinical outcomes in Indian patients. Indian Journal of Medical and Paediatric Oncology, 40(4), 100-500 - https://pmc.ncbi.nlm.nih.gov/articles/PMC6798608.
• Louis, R. A., Rajendranath, R., Ganesan, P., Sagar, T. G., & Krishnamurthy, A. (2012). First report of upfront gefitinib compared with chemotherapy in advanced NSCLC patients from South India: Analysis of 120 patients. Indian Journal of Medical & Paediatric Oncology, 33(3), 146–154 - https://pubmed.ncbi.nlm.nih.gov/23248420.
• Singh, A., Patil, V., Menon, N., More, S., Jain, S., Goud, S., Shah, D., Shah, M., Jobanputra, K., & Ubharay, A. (2024). Long-term survival outcomes of gefitinib (Geftinat®) 250 mg versus carboplatin–pemetrexed chemotherapy in EGFR‑mutated advanced non‑small cell lung cancer: A Phase III randomized trial. Cancer Research, Statistics, and Treatment, 7(1), 19–26.
• Singh, A., Patil, V., Menon, N., More, S., Jain, S., Goud, S., Shah, D., Shah, M., Jobanputra, K., & Ubharay, A. (2024). Long‑term survival outcomes of gefitinib (Geftinat®) 250 mg versus carboplatin–pemetrexed chemotherapy in EGFR‑mutated advanced non‑small cell lung cancer: A Phase III randomized trial. Cancer Research, Statistics, and Treatment, 7(1), 19–26.
• Talvar, V., Vaid, A. K., Doval, D. C., Gupta, S., Sharma, J. B., & Sarin, J. (2006). EGFR inhibitor gefitinib in advanced pretreated non‑small cell lung cancer patients: Experience from a centre in North India. Journal of Clinical Oncology, 24(18), 17141.